Trovagene (TROV) Misses Q4 EPS by 1c

Trovagene (NASDAQ: TROV) reported Q4 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25).

2016 Goals and Objectives

• Continue to build clinical evidence supporting the use of Trovagene's PCM platform
  • Submit 8 or more abstracts for presentation at key medical meetings in 2016
  • Submit up to 9 clinical and scientific manuscripts for publication that demonstrate the technical advantages and clinical utility of Trovagene's PCM platform
• Establish advantageous reimbursement relationships with third party administrators
  • Secure agreements representing more than 100 million covered lives
  • Finalize comprehensive health-economic study plan
• Establish marketing and adoption parameters
  • Ensure high clinical interest and strong service levels
  • Expand sales and marketing presence in the oncology market
  • Conduct and document real-world case studies
• Engage in strategic partnerships for clinical trial service agreements and translational research collaborations, and to expand global presence
• Conduct clinical studies with top academic institutions and comprehensive cancer centers

For earnings history and earnings-related data on Trovagene (TROV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c